- Home
- REBN vs VRAX Comparison
REBN vs VRAX Comparison
Compare REBN & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REBN | VRAX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 2.9M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | REBN | VRAX |
|---|---|---|
| Price | $1.47 | $0.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 56.9K | ★ 15.4M |
| Earning Date | 11-19-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,663,303.00 | $2,986.00 |
| Revenue This Year | $335.98 | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.09 | N/A |
| 52 Week Low | $1.20 | $0.35 |
| 52 Week High | $8.30 | $3.20 |
Technical Indicators
Market Signals| Indicator | REBN | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 40.67 | 41.23 |
| Support Level | $1.40 | $0.39 |
| Resistance Level | $1.80 | $0.43 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 19.30 | 3.23 |
Price Performance
Historical ComparisonAbout REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).